使用单克隆抗CD20抗体利妥昔单抗治疗眼眶良性假淋巴瘤。
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
作者信息
Witzig Thomas E, Inwards David J, Habermann Thomas M, Dogan Ahmet, Kurtin Paul J, Gross John B, Ananthamurthy Anuradha, Ristow Kay M, Garity James A
机构信息
Department of Internal Medicine, Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
出版信息
Mayo Clin Proc. 2007 Jun;82(6):692-9.
OBJECTIVE
To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab.
PATIENTS AND METHODS
Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab.
RESULTS
Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab.
CONCLUSION
Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.
目的
报告使用抗CD20单克隆抗体利妥昔单抗治疗眼眶假淋巴瘤患者的结果。
患者与方法
纳入1998年1月1日至2005年12月31日期间有眼眶肿物且经活检证实为眼眶假淋巴瘤的患者进行研究。该研究聚焦于接受利妥昔单抗治疗的患者。
结果
共评估了98例患者，活检结果显示72例（73%）为恶性非霍奇金淋巴瘤；另外26例（27%）为假淋巴瘤。26例假淋巴瘤患者中有11例（42%）接受了利妥昔单抗治疗，剂量为375 mg/m²，静脉注射，每周1次，共4剂，其中11例中有10例（91%）有反应。7例患者接受了利妥昔单抗维持治疗，或在复发后成功接受利妥昔单抗再次治疗。10例有反应的患者中无一例对利妥昔单抗产生耐药。
结论
良性淋巴细胞增生性肿瘤对靶向B淋巴细胞的单克隆抗体治疗有反应。利妥昔单抗应被视为眼眶假淋巴瘤的一种治疗选择。
Zotero 插件